WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and Adolor Enter into Exclusive Worldwide Collaboration 06 December 2007
Pfizer to Acquire Coley Pharmaceutical Group 16 November 2007
Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function 06 November 2007
Taisho and Pfizer Sign a Letter of Intent for Taisho’s Schizophrenia Drug Candidate 03 November 2007
Pfizer to Appeal German Court Decision in Lipitor Patent Case 30 October 2007
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent 23 October 2007
Pfizer Reports Third-Quarter 2007 Results 19 October 2007
Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care 15 October 2007
Pfizer Launches Independent Biotherapeutics and Bioinnovation Center 05 October 2007
Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer 28 September 2007
First in a New Oral Class of HIV Medicines in 10 Years 24 September 2007
Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug 19 September 2007
Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib 12 September 2007
Pfizer Launches Five Year, Three Country Initiative for Malaria Treatment and Education 06 September 2007
Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death 05 September 2007
Pfizer Names Frank A. D'Amelio Chief Financial Officer 22 August 2007
UK Body Recommends Pfizer's Champix (varenicline) for Smokers 30 May 2007
  • Start
  • Prev
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
  • Research identifies, exploits vulnerability in certain high-risk cancers
  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.